1,3 A 2025 systematic review in the International Journal of Dermatology confirmed that among GLP-1 receptor agonists, semaglutide and tirzepatide showed the highest reported incidence of hair loss, with telogen effluvium and androgenetic alopecia (AGA) identified as the predominant subtypes
Electrophoresis 18 , 27142723 (1997)
According to FDA labeling, no dose adjustment is required in patients with renal impairment, including those with end-stage renal disease (ESRD)
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease
Many people in the health optimization space are asking the same question right now
Over time, both compounds have appeared in numerous scientific studies exploring receptor interactions, peptide signalling dynamics and molecular regulatory mechanisms